MiNK Therapeutics (INKT) Reports $0.2M First Product Revenue; ARDS Data Expected 2H2027

MiNK reported $0.2M in first pre-commercial agenT-797 revenue and a Q3 net loss of $2.6M, or $0.50 per share, versus $2.9M, or $0.65 per share, a year earlier. Its randomized ARDS trial continued enrolling; data are expected 2H2027.Material DetailsContext by AI AnalystThis is an early commercial an…